Results 41 to 50 of about 8,310 (206)
Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents [PDF]
, 2016 The clinical management of medication-related osteonecrosis of the jaw (MRONJ) in patients treated with bisphosphonates and other antiresorptive agents is subject to controversy.
Oñate Sánchez, Ricardo Elías +1 more
core +1 more source
Dentistry Journal, 2018 The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients.
Vittorio Fusco +6 more
doaj +1 more source
Maxillofacial Plastic and Reconstructive Surgery, 2023 Background Risk factors for developing medication-related osteonecrosis of the jaw (MRONJ) include the general condition of the patient, smoking habit, poor oral hygiene, and the type, duration, and administration route of the drug, dentoalveolar surgery,
Yong-Dae Kwon +3 more
doaj +1 more source
Concept, diagnosis and classification of bisphosphonate-associated osteonecrosis of the jaws: a review of the literature [PDF]
, 2016 Background: Bisphosphonates (BPs) and other antiresorptive agents such as denosumab are widely prescribed for the treatment of osteoporosis and are also used in patients with multiple myeloma and metastatic breast or prostate cancer for avoiding bone ...
Bagán Sebastián, José Vicente +1 more
core +1 more source
Curious Case of Rodent Poison: A Case Report [PDF]
, 2021 Osteonecrosis was first described as a consequence of ionizing radiation used in the treatment of malignant tumors but later a variety of causes for osteonecrosis were found which include, Medication induced, radiation induced, chemical induced and ...
B. Senthil Kumar +3 more
core +2 more sources
The Prevention of Medication-related Osteonecrosis of the Jaw [PDF]
Deutsches Ärzteblatt international, 2017 Medication-related osteonecrosis of the jaw (MRONJ) is a preventable complication of antiresorptive treatment. It arises in 1-20% of patients with bone metastases of solid tumors and hematologic malignancies and in 0.1-2% of patients being treated for osteoporosis with bisphosphonates. Depending on the underlying disease and medication dosage, the risk
Poxleitner, Philipp +3 more
openaire +3 more sources
Medication-related osteonecrosis of the jaw: An update
National Journal of Maxillofacial Surgery, 2022 Antiresorptive medications, such as bisphosphonates and denosumab, are an important class of medication used to treat a wide range of diseases from osteoporosis to multiple myeloma. Unfortunately, they are also associated with a rare but devastating side effect - medication-related osteonecrosis of the jaw (MRONJ). First reported in 2003, much research
openaire +2 more sources
Therapeutic Effect of Benidipine on Medication-Related Osteonecrosis of the Jaw
Pharmaceuticals, 2022 Medication-related osteonecrosis of the jaw (MRONJ) is an intractable disease that is typically observed in patients with osteoporosis or tumors that have been treated with either bisphosphonate (BP) or antiangiogenic medicine.
Ken Matsunaka +7 more
doaj +1 more source
Osteonecrosis of the Jaw After Bisphosphonates Treatment in Patients with Multiple Myeloma [PDF]
, 2015 Bone lytic lesion in Multiple myeloma are the most commonly presented symptoms which require treatment with bisphosphonates (BPs). BPs are providing supportive care, reducing the rate of skeletal morbidity but evidently not abolishing it, the criteria ...
Alan Archibald (45342) +21 more
core +3 more sources
Prognosis factors in the treatment of bisphosphonate-related osteonecrosis of the jaw - Prognostic factors in the treatment of BRONJ - [PDF]
, 2014 Objectives: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a relatively rare but serious side effect of bisphosphonate (BP)-based treatments. This retrospective study aimed to investigate the risk factors and predictive markers in cases where
Kaneuji, Takeshi +13 more
core +1 more source